NASDAQ · ACXP
Acurx Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACXP: Nov 12, 2026
Acurx Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/12/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.45. The reported EPS for the same quarter last year was $-1.23.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Dec 2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · Fintel- RTTNews · Aug 18, 1:29 AM EDTAcurx Gets FDA Conditional Acceptance, U.S. Patents Trademark Allowance For Ibezapolstat Brand Name(RTTNews) – Acurx Pharmaceuticals, Inc. (ACXP), a late-stage biopharmaceutical company, on Monday announced that the U.S. FDA has conditionally accepted CIFBEZY as the proposed proprietary name for its lead antibiotic candidate Ibezapolstat.
- Zacks · Jun 8, 12:00 PM EDTAcurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's WhyAcurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- The Motley Fool · May 12, 12:45 PM EDTAcurx (ACXP) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Apr 16, 9:21 AM EDTAcurx Pharma Prices $7.1 Mln Offering Of Shares And Short-Term Warrants; Stock Down(RTTNews) – Acurx Pharmaceuticals, Inc. (ACXP), a late-stage biopharmaceutical company announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 0.825 million shares at a purchase price of $3.03 per share in a registered direct offeri
- Zacks · Apr 2, 9:40 AM EDTIs Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
- Zacks · Mar 19, 9:55 AM EDTCan Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Mar 17, 9:40 AM EDTIs Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
- RTTNews · Mar 10, 4:36 AM EDTAcurx Pharma To Conduct New Ibezapolstat Clinical Trial In RCDI; Advances Phase 3 Trial For CDI(RTTNews) – Acurx Pharmaceuticals, Inc. (ACXP), a late-stage biopharmaceutical company, announced that it will conduct a new clinical trial with Ibezapolstat in patients with recurrent Clostridioides difficile Infection (rCDI).In parallel, the firm is advancing to Phase 3 interna
- Zacks · Jan 6, 9:40 AM ESTHas Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
- Fintel · Sep 30, 8:03 PM EDTHC Wainwright & Co. Reiterates Acurx Pharmaceuticals (ACXP) Buy RecommendationFintel reports that on September 30, 2025, HC Wainwright & Co. reiterated coverage of Acurx Pharmaceuticals (NasdaqCM:ACXP) with a Buy recommendation. Analyst Price Forecast Suggests 1,356.81% Upside
- RTTNews · Sep 30, 10:11 AM EDTAcurx Pharmaceuticals Wins Positive Response From EMA On Ibezapolstat Use In Children(RTTNews) – Acurx Pharmaceuticals, Inc. (ACXP), Tuesday announced receipt of a favorable opinion from the Paediatric Committee or PDCO of the European Medicines Agency on its Pediatric Investigation Plan for ibezapolstat use in children with C. difficile infection.
- RTTNews · Jul 31, 6:22 PM EDTAcurx Approves 1-for-20 Reverse Stock Split To Regain Nasdaq Compliance(RTTNews) – Acurx Pharmaceuticals (ACXP) announced a 1-for-20 reverse stock split of its common shares, set to take effect on August 4, 2025.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Acurx Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.